Evidence map›Paper›PMID 41477181›Full record

ArticleDrug design, development and therapy2025

Preliminary Developmental Safety Assessment of Allylestrenol in Pregnant SD Rats: Evaluation of F0 and Early F1 Generational Endpoints.

Lai Jiang, Shengnan Zhuan, Wenjie Jin, He Wen, Dajin Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lai JiangDepartment of Obstetrics and Gynecology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, People's Republic of China.
Shengnan ZhuanDepartment of Obstetrics and Gynecology, Bengbu Medical University, Bengbu, Anhui, 233030, People's Republic of China.
Wenjie JinTianjin Tiancheng New Drug Evaluation Co., Ltd, Tianjin, People's Republic of China.ORCID 0009-0000-1747-9976
He WenTianjin Tiancheng New Drug Evaluation Co., Ltd, Tianjin, People's Republic of China.
Dajin LiHaboratory of Reproduction Immunology, Shanghai Key Laboratory of Female Reproductive Endocrine Related Diseases, Obstetrics and Gynecology Hospital, Fudan University Shanghai Medical College, Shanghai, 200001, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: The objective of this study was to evaluate the developmental and hormonal safety profile of different doses of allylestrenol administered during gestation in SD rats, focusing on selected physiological and reproductive indices in the Parental (F0) and First-generation offspring (F1) generations. Methods: In this study, 138 successfully mated Sprague-Dawley (SD) female rats were randomly divided into solvent control (Sol-C), progesterone injection control (PgI-C), progesterone soft-gel capsule control (PgSC-C), low-dose allylestrenol (Alt-LD, 5 mg kg Results: Estradiol levels on gestation day 19 (GD Conclusion: Allylestrenol at doses of 5, 10, and 20 mg kg

Indexed as

AllylestrenolMaternal ExposureAnimalsDose-Response Relationship, DrugFemaleMalePregnancyRatsRats, Sprague-DawleyReproductionAllylestrenolallylestrenolnormal pregnancyprogesteronereproductive toxicitySD rats

Identifiers

PMID41477181
PMCPMC12751335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.